NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use

RecruitingN/A

Sponsor: Otsuka Pharmaceutical Co., Ltd.

Conditions: Migraine Disorders

Interventions: Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution

Countries: Japan

To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

\-

Exclusion Criteria:

* patients with a known hypersensitivity to components of AJOVY

Locations (1)

Osaka, Japan